Signals, Powered By EquityPandit
In the latest effort by government for improving the affordability of medicines, the country has extended price caps to 39 more medicines that are ranging from commonly used diabetes drugs to antibiotics.
The National Pharmaceutical Pricing Authority (NPPA) has posted a notice on its website which detailed the 39 new drugs, which extend a price control list that already includes more than 652 medicines.
This move impacts multinational drug makers like Abbott Laboratories (ABT.N) and GlaxoSmithKline PIc (GSK.L), and also a number of local firms that includes Lupin Ltd (LUPN. NS), Cadila Healthcare Ltd(CADI.NS) and Ipca Ltd (IPCA.NS), all of whom sell drugs added to the list.
